AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01534169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: The course of treatment will be last for 3 months. The intrathyroid injection of dexamethasone will be performed using a 25-gauge (0.25-mm) needle under ultrasound guidance. The injection will be performed in both lobes of the thyroid. The dosage of dexamethasone is 5mg (1.0 ml) in each lobe, twice a week during the first month of the treatment. The treatment strategy will be changed to once a week in the second month and twice a month in the third month; the dosage of dexamethasone is the same as in the first month.
Study NCT04574687 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurodevelopmental Techniques
Description: )Conventional treatment protocol including active and active-assissted ROM exercises. (b)Proprioceptive neuro-muscular facilitation techniques. (c)Neuromuscular Developmental Techniques.
Study NCT00916110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATN-103
Description: 4 mg solution, single subcutaneous injection
Study NCT00916110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATN-103
Description: 10 mg solution, single subcutaneous injection
Study NCT00916110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATN-103
Description: 25 mg solution, single subcutaneous injection
Study NCT00916110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATN-103
Description: 25 mg solution, single intravenous injection
Study NCT00484939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Treatment continued until unacceptable toxicity, withdrawal of consent, disease progression, or a decision to terminate at the discretion of the Investigator if medically indicated. Capecitabine was supplied as tablets.
Study NCT05084573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Single bolus injection 10mL 1.33% LB
Study NCT05084573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard bupivacaine
Description: Single bolus 10mL 0.25% SB + continuous 300mL 0.2% SB @5mL/hr
Study NCT01751386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen
Study NCT00916110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATN-103
Description: 50 mg solution, single subcutaneous injection
Study NCT00916110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATN-103
Description: 100 mg solution, single subcutaneous injection
Study NCT00916110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATN-103
Description: 200 mg solution, single subcutaneous injection
Study NCT00916110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATN-103
Description: 200 mg solution, single intravenous injection
Study NCT05488990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKVANO-Calcipotriol formulation 1
Description: Novel lipid based formulation (AKVANO) type 1 containing Calcipotriol (50 μg/g)
Study NCT01751386 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04087187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Subject will be given AZD5718 Dose A tablet once daily
Study NCT04574687 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action observation Therapy
Description: (a) active range of motion (AROM) exercises (10 min), (b) reaching movement or object manipulation (10 min), and (c) UE functional tasks (15 min). + Conventional treatment protocol as in group A
Study NCT03741400 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neofect RAPAEL Smart Glove
Description: The Neofect Rapael Smart Glove is a biofeedback system designed for upper extremity rehabilitation in stroke survivors. It includes a glove-shaped sensor device and a software application.
Study NCT05488990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKVANO-Calcipotriol formulation 2
Description: Novel lipid based formulation (AKVANO) type 2 containing Calcipotriol (50 μg/g)
Study NCT05488990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKVANO vehicle formulation 1
Description: Novel lipid based formulation (AKVANO) vehicle 1
Study NCT05488990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKVANO vehicle formulation 2
Description: Novel lipid based formulation (AKVANO) vehicle 2
Study NCT05488990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daivonex solution
Description: Daivonex solution containing Calcipotriol (50 μg/g)
Study NCT05488990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daivonex cream
Description: Daivonex cream containing Calcipotriol (50 μg/g)
Study NCT00837291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CF101
Description: CF101 tablets 1 mg BID
Study NCT00837291 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets BID
Study NCT00502684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol, etodolac
Description: propranolol 10 mg X 4 /day, starting on day -3 pre-op, for 6 days, till POD 2 Etodolac 400 mg X2/day, starting on day -3 pre-op, for 6 days, till POD 2
Study NCT00612664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-CD137 (4-1BB) (BMS-663513)
Description: IV solution, IV, until PD or toxicity
Study NCT02822703 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS Active 20Hz
Description: Active stimulation will be delivered with 70mm Double Air Film Coils. Participants will attend eight 20Hz sessions within two weeks of the scheduled quit date. Participants will receive 20Hz at 110% of the MT for 1 second, less than the limits indicated in the guidelines. These stimulation parameters have been utilized with no serious adverse events in previous studies to decrease delay discounting among smokers and non-smokers. These parameters are similar to or less intense than those utilized in other smoking cessation studies. All participants will receive rTMS over the same area of the DLPFC (6cm anterior to the MT area) while reading relapse prevention booklets supervised by the study coordinator.
Study NCT01857479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled budesonide
Description: The control group will receive only nebulized budesonide 1 mg b.i.d. thrice a week for four months. Patients will also receive a metered dose inhaler of formoterol/budesonide (6/200) at a dose of 2 puffs b.i.d. and as and when required \[max 10 puff/day\]. The first dose will be administered under direct supervision. If the first dose is tolerated, therapy would be continued for the total duration of the study (4 months). The patient will be advised to clean the nebulizer chamber with soap and water after each administration to avoid contamination.
Study NCT02822703 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS Sham
Description: The sham stimulation uses a similar 70mm Double Air Film Coil to look and sound like the active coil, but the magnetic field produced by the sham coil is markedly attenuated (only 5% of stimulator output setting: that is 2.25% of the maximum stimulator output (5% of 45% = 2.25%) and biologically inactive. Participants in this condition will attend eight sham sessions within two weeks of their scheduled quit date. During these sessions, they will also read relapse prevention booklets supervised by the study coordinator. The sham coil is not intended to and does not produce a stimulation effect so there is no proposed biologic mechanism of action.
Study NCT03033667 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: G group
Description: patients received 500 cc of glucose 10% containing 50 g of glucose proving patients with 200 Kcal with 556 mosmoles/L
Study NCT03033667 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: group L
Description: patients received 100 cc of lipid solution (soybean 30%, medium chain triglycerides 30%,olive oil 25%,fish oil 15% and 20 mg vitamine E) containing 20 g lipid which provided patients with 200 Kcal with osmolarity of 380 mosmoles /L. with a flow rate of infusion of 12.5 cc per hour
Study NCT03033667 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Group C
Description: Over night fasting with no supplementation
Study NCT01727167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200ppm CO for one hour
Description: This is the study intervention. The treatment group will breath 200 ppm of CO for one hour over the three days immediately prior to surgery.
Study NCT01727167 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: This group will breath room air for one hour per day over the course of the three days immediately prior to surgery.
Study NCT01857479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Description: The control group will receive only nebulized budesonide 1 mg b.i.d. thrice a week for four months. Patients will also receive a metered dose inhaler of formoterol/budesonide (6/200) at a dose of 2 puffs b.i.d. and as and when required \[max 10 puff/day\]. The first dose will be administered under direct supervision. If the first dose is tolerated, therapy would be continued for the total duration of the study (4 months). The patient will be advised to clean the nebulizer chamber with soap and water after each administration to avoid contamination.
Study NCT01857479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled amphotericin
Description: Amphotericin B deoxycholate (50 mg) will be dissolved in 10 mL sterile water for injection (5 mg/mL). The solution remains stable for at least 7 days at 2°C to 8°C. Ten milligrams of the drug (2 mL) will be nebulized over 10-15 minutes twice in a day for three times a week (Effective dose: 10 mg b.i.d. thrice a week) using a jet nebulizer. Nebulized budesonide will be administered at a dose of 1 mg b.i.d. thrice a week after nebulization with amphotericin B. The total duration of therapy would last 4 months. Patients will also receive a metered dose inhaler of formoterol/budesonide (6/200) at a dose of 2 puffs b.i.d. and as and when required \[max 10 puff/day\].~The first dose will be administered under direct supervision.
Study NCT02800642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept (Eylea, BAY86-5321)
Description: The recommended dose for intravitreal aflibercept was 2 mg equivalent to 50 μL. Study treatment was administered at baseline and at monthly intervals until stabilization of disease. When stability was achieved, the treatment interval could be extended based on visual and anatomic outcomes as judged by the treating investigator.
Study NCT04087187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Subjects will be given AZD5718 Dose B tablet once daily
Study NCT00458783 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged RBC storage
Description: Transfusion with oldest available matching RBCs
Study NCT00458783 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Short RBC storage
Description: Transfusion with youngest available matching RBCs
Study NCT02372799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilazodone
Study NCT02372799 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03266172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2982772 Modified Release
Description: GSK2982772 MR will be available as prototype MR minitablet in capsules with unit dose strength of 60 mg in Part A. In Part B, GSK2982772 MR minitablet in capsules with unit dose strength of 15, 30 or 60 mg will be administered by subjects for Days 1 to 3. In Part C, GSK2982772 MR tablet with unit dose strength of 240, 360 or 480 mg will be administered by subjects. GSK2982772 MR will be administered orally with 240 mL of water.
Study NCT03266172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2982772 Immediate Release
Description: In part A, GSK2982772 IR tablet will be available with unit dose strength of 30 mg and the total dose administered by subjects will be 120 mg (4 tablets of dose strength 30 mg) orally with 240 mL of water. In part C, GSK2982772 IR tablet will be available with unit dose strength of 30 mg and the total dose administered by subjects will be 240 mg (8 tablets of dose strength 30 mg) orally with 240 mL of water.
Study NCT03779503 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: midafilcon A
Description: midafilcon A 1 day daily disposable contact lens
Study NCT02372799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Study NCT04582994 — intervention group
Intervention type: BEHAVIORAL
Intervention: Beta tACS
Description: participants perform the Mental Time Travel task (duration 20 minutes), while tACS stimulation is delivered at Beta frequencies (22 Hz)
Study NCT04582994 — intervention group
Intervention type: BEHAVIORAL
Intervention: Alfa tACS
Description: participants perform the Mental Time Travel task (duration 20 minutes), while tACS stimulation is delivered at Alfa frequencies (10 Hz)
Study NCT04582994 — intervention group
Intervention type: BEHAVIORAL
Intervention: Sham
Description: participants perform the Mental Time Travel task (duration 20 minutes), while Sham tACS stimulation is delivered
Study NCT01184027 — intervention group
Intervention type: BEHAVIORAL
Intervention: nutrition /swallowing counseling
Description: general nutrition and swalling information
Study NCT01184027 — intervention group
Intervention type: BEHAVIORAL
Intervention: G-tube/swallowing intervention
Description: Patient will have active swallowing intervention with an SLP
Study NCT04087187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Subjects will be given AZD5718 Dose C tablet once daily
Study NCT03779503 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: somofilcon A
Description: somofilcon A 1 day daily disposable contact lens
Study NCT02907749 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone and carvedilol
Description: Patients are treated with carvedilol in combination with spironolactone.
Study NCT02907749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Patients are treated with carvedilol only.
Study NCT03344263 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: tests of attentional performance
Description: tests of attentional performance before and after 6 months of continuous positive airways pressure
Study NCT04489121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: For patients in the Omalizumab group, subcutaneous injections of Omalizumab based on the specific participant's weight and serum total IgE was performed 2 weeks prior the anticipated pollen season.
Study NCT01203358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exosurf
Description: Infants received up to four intratracheal doses of the surfactant.
Study NCT01203358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Survanta
Description: Infants received up to four intratracheal doses of the surfactant.
Study NCT00994591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic dosing
Description: Pharmacokinetic testing involves dosing with deuterated cotinine which has an associated IND#61329.
Study NCT02203955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Short-Chain Fructooligosaccharide
Description: 4 chews (8.0 g scFOS) orally for 12 months
Study NCT02203955 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: 4 chews (maltodextrin) daily for 12 months
Study NCT02334488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Active Comparator
Study NCT02334488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Active Comparator
Study NCT02334488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Active Comparator
Study NCT02334488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate sodium
Description: Experimental Arm
Study NCT01189292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 8mg (2ml) of dexamethasone (Mephameson®) administered intravenously preoperatively before thyroid surgery
Study NCT01189292 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%
Description: 2ml of NaCl 0.9% administered intravenously preoperatively before thyroid surgery
Study NCT02459275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEP uP Protocol
Description: Semi-elemental tube feeds are started at the hourly goal rate as determined by the 24 hour volume goal. Protein supplements will be started at the initiation of tube feeds to target a daily delivery of 2 g/kg/day.
Study NCT02459275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Description: Metoclopramide 10mg Intravenous (IV) every 6 hours (q6h) or 5mg IV q6h for renal failure will be started empirically concomitant with EN initiation. Gastric Residual Volume (GRV) will be checked every 4 hours and will be reinfused to the patient each time it is checked.
Study NCT06264284 — intervention group
Intervention type: PROCEDURE
Intervention: epidural anesthesia
Description: Emergency cesarean section (red code) with epidural anesthesia
Study NCT06264284 — intervention group
Intervention type: PROCEDURE
Intervention: general anesthesia
Description: Emergency cesarean section (red code) with general anesthesia
Study NCT03825237 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Polysomnography
Description: The polysomnography (referred to as type I) allows assessing several sleep physiologic parameters (eg, EEG, electrooculogram, electromyogram, electrocardiogram, airflow, respiratory effort, oxygen saturation), whereas audio-video recording enables documenting tooth-grinding sounds and distinguishing between rhythmic masticatory muscle activity (RMMA) and orofacial (eg, swallowing) and other muscular activity (eg, head movements) during sleep. Based on the RMMA index (number of episodes per hour of sleep), sleep bruxism is diagnosed when RMMA episodes are greater than or equal to 2 (low-frequency SB, mild bruxism) or RMMA episodes are greater than or equal to 4 (high-frequency SB, severe bruxism)
Study NCT02066415 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Erenumab
Description: Administered once a month subcutaneously by authorized investigational site study staff.
Study NCT02066415 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: Administered once a month subcutaneously by authorized investigational site study staff.
Study NCT02066415 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered once a month subcutaneously by authorized investigational site study staff.
Study NCT03303612 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Pacemaker implant
Description: Patient will be in the electrophysiology laboratory. The doctor will freeze the groin area and a medication may be given to help the patient relax. A catheter will be inserted into the groin up to the heart and the heart's electrical system will be recorded.
Study NCT03303612 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Transcutaneous cardiac monitor
Description: Transcutaneous cardiac patches will allow continuous electrocardiographic monitoring for a 30-day period. For the first randomized patients at the Montreal Heart Institute, Icentia was used and then was changed to a m-Health® device which allows continuous cardiac monitoring. The PocketECG from m-Health® is attached to 3 electrodes on the chest and contains a SIM card that transmits to a server located in Burlington, Ontario .The COME-TAVI coordinating center and the associated site will be informed rapidly of any events that occur . These events include:~Ventricular fibrillation; Sustained ventricular tachycardia Any RR interval >5 sec; Third-degree AV block or Mobitz 2 AV block;
Study NCT05605171 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior reconstruction urethrovesical anastomosis.
Description: Rocco stitch.
Study NCT05605171 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional vesicourethral anastomosis.
Description: Standard of care.
Study NCT01120795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon and ribavirin
Description: Pegylated interferon 180 ug subcutaneous per week Ribavirin 1000-1200 mg /day for genotype 1 and 800 mg /day orally for genotype non 1 Duration: 48 weeks for genotype 1 and 24 weeks for gentoype non 1
Study NCT01120795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon and ribavirin
Description: Pegylated interferon 180 ug/ week subcutaneously Ribavrin 1000-1200 mg /day for genotype 1 and 800 mg/day orally for genotype 2 and 3 Treatment duration 48 weeks for genotype 1 and 24 weeks for genotypes 2 and 3
Study NCT01533922 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo matching tiotropium + olodaterol FDC
Study NCT01533922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Tiotropium 5 mcg once daily
Study NCT01533922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olodaterol
Description: Olodaterol 5 mcg once daily
Study NCT01533922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium + olodaterol
Description: tiotropium + olodaterol 5 mcg once daily
Study NCT01533922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium + Olodaterol
Description: Tiotropium 2.5 mcg + Olodaterol 5 mcg once daily
Study NCT01533922 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respimat
Description: Respimat inhaler